• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lefamulin-A New Antibiotic for Community-Acquired Pneumonia.

作者信息

Malani Preeti N

机构信息

Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor.

Associate Editor, JAMA.

出版信息

JAMA. 2019 Nov 5;322(17):1671-1672. doi: 10.1001/jama.2019.16215.

DOI:10.1001/jama.2019.16215
PMID:31560367
Abstract
摘要

相似文献

1
Lefamulin-A New Antibiotic for Community-Acquired Pneumonia.来法莫林——一种用于社区获得性肺炎的新型抗生素。
JAMA. 2019 Nov 5;322(17):1671-1672. doi: 10.1001/jama.2019.16215.
2
Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.利福霉素：一种新型半合成截短侧耳素抗生素，用于治疗社区获得性细菌性肺炎。
Clin Infect Dis. 2020 Dec 17;71(10):2757-2762. doi: 10.1093/cid/ciaa336.
3
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.截短侧耳素类抗生素静脉至口服给药的来法莫林治疗社区获得性细菌性肺炎的疗效和安全性：III期来法莫林抗肺炎评估（LEAP 1）试验
Clin Infect Dis. 2019 Nov 13;69(11):1856-1867. doi: 10.1093/cid/ciz090.
4
Lefamulin: The First Systemic Pleuromutilin Antibiotic.利福霉素：首个系统应用的截短侧耳素类抗生素。
Ann Pharmacother. 2020 Dec;54(12):1203-1214. doi: 10.1177/1060028020932521. Epub 2020 Jun 4.
5
Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia.左氟沙星治疗社区获得性肺炎的治疗潜力。
Future Microbiol. 2019 Jul;14:927-939. doi: 10.2217/fmb-2019-0027. Epub 2019 Jul 23.
6
Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
Clin Infect Dis. 2020 May 23;70(11):2459. doi: 10.1093/cid/ciz710.
7
Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.利福霉素：一种有前途的新型截短侧耳素类抗生素的综述。
Pharmacotherapy. 2018 Sep;38(9):935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20.
8
Emerging antibiotics for community-acquired pneumonia.用于社区获得性肺炎的新型抗生素。
Expert Opin Emerg Drugs. 2019 Dec;24(4):221-231. doi: 10.1080/14728214.2019.1685494. Epub 2019 Nov 1.
9
Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.在两项III期随机、双盲、双模拟临床试验中，对接受来法莫林或莫西沙星治疗的社区获得性细菌性肺炎成年住院患者临床反应时间的事后评估。
Open Forum Infect Dis. 2020 Apr 24;7(5):ofaa145. doi: 10.1093/ofid/ofaa145. eCollection 2020 May.
10
Lefamulin来法莫林

引用本文的文献

1
Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF3 in Hepatocellular Carcinoma.左氟沙星通过靶向 ILF3 调控肝癌线粒体稳态克服获得性耐药。
Adv Sci (Weinh). 2024 Aug;11(30):e2401789. doi: 10.1002/advs.202401789. Epub 2024 Jun 14.
2
Inhibition of bacterial RNA polymerase function and protein-protein interactions: a promising approach for next-generation antibacterial therapeutics.抑制细菌RNA聚合酶功能和蛋白质-蛋白质相互作用：下一代抗菌疗法的一种有前景的方法。
RSC Med Chem. 2024 Mar 26;15(5):1471-1487. doi: 10.1039/d3md00690e. eCollection 2024 May 22.
3
Nanophysical Antimicrobial Strategies: A Rational Deployment of Nanomaterials and Physical Stimulations in Combating Bacterial Infections.
纳米物理抗菌策略：在抗菌感染中合理运用纳米材料和物理刺激
Adv Sci (Weinh). 2022 Apr;9(10):e2105252. doi: 10.1002/advs.202105252. Epub 2022 Jan 27.
4
Aging Immune System and Its Correlation With Liability to Severe Lung Complications.衰老的免疫系统及其与严重肺部并发症易感性的关系。
Front Public Health. 2021 Nov 23;9:735151. doi: 10.3389/fpubh.2021.735151. eCollection 2021.
5
Knowledge Gaps in the Understanding of Antimicrobial Resistance in Canada.加拿大对抗菌药物耐药性理解的知识差距。
Front Public Health. 2021 Oct 20;9:726484. doi: 10.3389/fpubh.2021.726484. eCollection 2021.
6
Antibacterial Activity of a Promising Antibacterial Agent: 22-(4-(2-(4-Nitrophenyl-piperazin-1-yl)-acetyl)-piperazin-1-yl)-22-deoxypleuromutilin.新型抗菌剂：22-(4-(2-(4-硝基苯基-哌嗪-1-基)-乙酰基)-哌嗪-1-基)-22-去氧苦霉素的抗菌活性。
Molecules. 2021 Jun 8;26(12):3502. doi: 10.3390/molecules26123502.
7
Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.来法莫林与莫西沙星治疗社区获得性细菌性肺炎的比较
Medicine (Baltimore). 2020 Jul 17;99(29):e21223. doi: 10.1097/MD.0000000000021223.
8
The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.解决淋病奈瑟菌抗生素耐药性的前沿问题。
Transl Res. 2020 Jun;220:122-137. doi: 10.1016/j.trsl.2020.02.002. Epub 2020 Feb 29.